Synthetic cell research group accidentally builds a factory
New CapabilitiesSan Francisco plant makes open-source cell-building reagents after key suppliers quit
Yesterday: Hundredth Cytosol kit shippedNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated YesterdayRoche stopped making tRNA in 2023; Sigma stopped in 2024. With the only two commercial sources of a critical molecule gone, a small research group in San Francisco built its own factory to make the missing ingredients.
The factory makes Cytosol, the core mix of proteins and reagents used to assemble synthetic cells in the lab. The group has shipped over 100 kits to roughly 20 labs worldwide. It is a side effect of a broken supply chain, not a grand vision.
The PURE system, the field's standard platform, was published in 2001. It took labs 18 months or more to build because the plasmid set was incomplete, mutated, and locked behind restrictive licenses. b.next redesigned all 36 plasmids, open-sourced the recipe, and now manufactures the final product.
Why it matters
Synthetic cells could make new drugs and materials, but only if labs can get the ingredients. This factory is the first open supply chain.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
An academic group that became a manufacturer of synthetic cell reagents.
Open commons where the synthetic cell community shares protocols, designs, and specifications.
Nonprofit supporting cell engineering research and community building.
Public-benefit institution for shared synthetic cell engineering infrastructure.
Timeline
2023 September 2026
-
Hundredth Cytosol kit shipped
Latest Milestoneb.next announced shipping its 100th kit, supporting open projects at roughly 20 labs.
-
SpudCell completes full life cycle
Research breakthroughUniversity of Minnesota team unveiled SpudCell, a synthetic cell that grows, replicates, and divides.
-
San Francisco Cytosol plant opens
InfrastructureOperationalized a manufacturing plant in San Francisco to supply Cytosol kits.
-
All PURE components open-sourced
MilestoneReleased open protocols for every PURE component, including tRNA and ribosomes.
-
First PURE workshop trains eight researchers
EventGraduate students and postdocs built the full PURE system from scratch in one week.
-
Open PURE plasmid set released
PublicationPublished redesigned 36-plasmid set and PURE assembly protocols on Nucleus.
-
Sigma exits tRNA market
Supply chainSigma also discontinued tRNA, leaving no commercial source of the molecule.
-
Roche exits tRNA market
Supply chainRoche discontinued tRNA, the first of two sole suppliers to exit the market.
-
b.next wins open synthetic cell contract
ContractReceived a contract to build a simple synthetic cell sensor from fully open components.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Genentech and recombinant insulin (1976–1982)
In 1976, venture capitalist Robert Swanson and biochemist Herbert Boyer founded Genentech to commercialize recombinant DNA. In 1982, human insulin produced by engineered bacteria became the first federally approved biotech drug, shifting insulin production from animal extraction to fermentation tanks.
Insulin manufacturing moved from slaughterhouses to bioreactors, and Genentech grew into a major pharmaceutical company.
Set the template for academic biology inventions being scaled by dedicated manufacturing companies. Most modern biotech drugs trace to this model.
Synthetic cells are at the same transition: lab inventions need factory infrastructure to reach practical scale, exactly what b.next's plant provides.
TSMC and the foundry model (1987)
Taiwan Semiconductor Manufacturing Company launched in 1987 as the world's first pure-play chip foundry. It offered manufacturing to any chip designer, no factory required, decoupling chip design from chip fabrication.
Fabless design firms multiplied, and TSMC became the dominant chip manufacturer globally.
Open manufacturing for all comers became the semiconductor standard, enabling the modern chip industry.
Cytosol resembles a foundry for synthetic cells: labs design, b.next manufactures the reagents. If the model works in biology, it could do for cell engineering what it did for chips.
Human Genome Project Bermuda Principles (1996)
At a 1996 meeting in Bermuda, leaders of the Human Genome Project agreed to release all genome sequence data within 24 hours of production. The project's data became a shared public asset instead of a proprietary one.
Sequencing data flowed openly, and the public consortium completed the human genome in 2003.
Established open-data norms in large-scale biology and seeded a genomics industry built on shared reference data.
The same bet underlies b.next's open Cytosol: shared core assets let the whole field build rather than gatekeeping access.
